Alzheimer's disease, estrogens, and clinical trials: A case study in drug development for complex disorders

Drug Development Research

Volumn 66, Issue 2, 2005, Pages 53-77

  Howell, Neil ^a,b   Dykens, James ^a   Moos, Walter H ^a,c,d  

^a MIGENIX Corporation   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SRI INTERNATIONAL   (United States)

Author keywords

amyloid; Alzheimer's disease; Clinical trials; Estrogens; Neurodegeneration; Neuroprotection; Presenilins

Indexed keywords

17ALPHA ESTRADIOL; ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; CONJUGATED ESTROGEN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME C; DONEPEZIL; ESTROGEN DERIVATIVE; GALANTAMINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULINASE; MEDROXYPROGESTERONE ACETATE; MEMANTINE; MITOGEN ACTIVATED PROTEIN KINASE; MX 4509; MX 4565; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NERVE GROWTH FACTOR; PRESENILIN 1; PRESENILIN 2; PROTEIN BAX; RALOXIFENE; RIVASTIGMINE; TACRINE; TAU PROTEIN; UNCLASSIFIED DRUG; ZYC 5;

ABSENCE OF SIDE EFFECTS; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; APOE GENE; APP GENE; BRAIN FUNCTION; BRAIN REGION; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL VIABILITY; CEREBROVASCULAR DISEASE; CLINICAL PATHWAY; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COLORECTAL CANCER; COST BENEFIT ANALYSIS; DISEASE ASSOCIATION; DRUG ANTAGONISM; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; ESTROGEN ACTIVITY; GENE; HIP FRACTURE; HIPPOCAMPUS; HUMAN; LONG TERM CARE; LONG TERM DEPRESSION; LONG TERM POTENTIATION; LUNG EMBOLISM; MENOPAUSAL SYNDROME; NERVE CELL PLASTICITY; NERVE FIBER MEMBRANE; NEUROANATOMY; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK BENEFIT ANALYSIS; SENILE PLAQUE; SIDE EFFECT;

EID: 33644839719     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20046     Document Type: Review

References (313)

1. Abraham IM, Todman MG, Korach KS, Herbison AE. 2003. Critical in vivo roles for classical estrogen receptors in rapid estrogen actions on intracellular signaling in mouse brain. Endocrinology 145:3055-3061.
2. Abramov AY, Canevari L, Duchen MR. 2004. β-Amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J Neurosci 24:565-575.
3. Acconcia F, Asdcenzi P, Bocedi A, Spisni E, Tomasi V, Trentalance A, Visca P, Marino M. 2005. Palmitoylation-dependent estrogen receptor α membrane localization: regulation by 17β-estradiol. Mol Biol Cell 16:231-237.
4. AD2000 Collaborative Group. 2004. Long-term donepezil treatment in 565 patients with Alzheimers disease (AD2000): randomized double-blind trial. Lancet 363:2105-2115.
5. Adams MM, Shah RA, Janssen WGM, Morrison JH. 2001. Different modes of hippocampal plasticity in response to estrogen in young and aged rats. Proc Natl Acad Sci USA 98:8071-8076.
6. Adams MM, Fink SE, Janssen WGM, Shah RA, Morrison JH. 2004. Estrogen modulates synaptic N-methyl-D-aspartate receptor sununit I distribution in the aged hippocampus. J Comp Neurol 474:419-126.
7. Akama KT, McEwen BS. 2003. Estrogen stimulates postsynaptic density-95 rapid protein synthesis via the Akt/protein kinase B pathway. J Neurosci 23:2333-2339.
8. Aliev G, Seyidova D, Lamb BT, Obrenovich ME, Siedlak SL, Vinters HV, Freidland RP, LaManna JC, Smith MA, Perry G. 2003. Mitochondria and vascular lesions as a central target for the development of Alzheimer's disease and Alzheimer disease-like pathology in transgenic mice. Neurol Res 25: 665-674.
9. Amieva H, Jacqmin-Gadda H, Orgogozo J-M, Le Carret N, Helmer C, Letenneur L, Barberger-Gateau P, Fabrigoule C, Dartigues J-F. 2005. The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain 128: 1093-1101.
10. Anandatheerthavarada HK, Biswas G, Robin MA, Avadhani NG. 2003. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol 161:41-54.
11. Anderer P, Saletu B, Gruber D, Linzmayer L, Semlitsch HV, Saletu-Zyhlarz G, Brandstatter, Metka M, Huber J. 2005. Age-related cognitive decline in the menopause: effects of hormone replacement therapy on cognitive event-related potentials. Maturitas 51:254-269.
12. Aucoin J-S, Jiang P, Aznavour N, Tong X-K, Buttini M, Descarries L, Hamel E. 2005. Selective cholinergic denervation, independent from oxidative stress, in a mouse model of Alzheimer's disease. Neuroscience 132:73-86.
13. 2+ channel modulation in the neuroprotective actions of estrogen in β-amyloid protein and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) cytotoxic models. Neurochem Int 45:31-38.
14. Baas PW, Qiang L. 2005. Neuronal microtubules: when the MAP is the roadblock. Trends Cell Biol 15:183-187.
15. Bake S, Sohnabji F. 2003. 17β-estradiol differentially regulates blood-brain barrier permeability in young and aging female rats. Endocrinology 145:5471-5475.
16. Bartus RT, Dean RI, Beer B, Lippa AS. 1982. The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408-414.
17. Beller GA. 2005. Lessons to be learned from the Vioxx debacle. J Nuclear Cardiol 12:1-2.
18. Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. 2004. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol 61:378-384.
19. Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. 2005. Mild cognitive impairment is related to Azlheimer disease pathology and cerebral infarctions. Neurology 64:834-841.
20. Berman K, Brodaty H. 2004. Tocopherol (vitamin E) in Alzheimer's disease and other neurodegenerative disorders. CNS Drugs 18: 807-825.
21. Bhavnani BR. 1998. Pharmacokinetics and pharmacodynamics of conjugated equine estrogens: chemistry and metabolism. Proc Soc Exp Biol Med 217:6-16.
22. Bhavnani BR, Cecutti A, Gerulath A, Woolever AC, Berco M. 2001. Comparison of the antioxidant effects of equine estrogens, red wine components, vitamin E, and probucol on low-density lipoprotein oxidation in postmenopausal women. Menopause 8:408-419.
23. Bi R, Broutman G, Foy MR, Thompson RF, Baudry M. 2000. The tyrosine kinase and mitogen-activated protein kinase pathways mediate multiple effects of estrogen in hippocampus. Proc Natl Acad Sci USA 97:3602-3607.
24. Biewenga E, Cabell L, Audesirk T. 2005. Estradiol and raloxifene protect cultured SN4741 neurons against oxidative stress. Neurosci Lett 373:179-183.
25. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. 2004. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA 101:2173-2178.
26. Blanchard V, Moussaoui S, Czech C, Touchet N, Bonici B, Planche M, Canton T, Jedidi I, Gohin M, Wirths O, Bayer TA, Langui D, Duychaerts C, Tremp G, Pradier L. 2003. Time sequence of maturation of dystrophic neurites associated with Aβ deposits in APP/PS1 transgenic mice. Exp Neurol 184:247-263.
27. Blizzard TA, DiNinno F, Chen HY, Kim S, Wu JY, Chan W, Birzin ET, Yang YT, Pai L-Y, Hayes EC, DaSilva CA, Rohrer SP, Schaeffer JM, Hammond ML. 2005. Estrogen receptor ligands. Part 13: Dihydrobenzoxathiin SERAMs with an optimized antagonist side chain. Bioorg Med Chem Lett 15:3912-3916.
28. Blomqvist ME-L, Chalmers K, Andreasen N, Bogdanovic N, Wilcock GK, Cairns NJ, Feuk L, Brookes AJ, Love S, Blennow K, Kehoe PG, Prince JA. 2005. Sequence variants of IDE are associated with the extent of β-amyloid deposition in the Alzheimer's disease brain. Neurobiol Aging 26:795-802.
29. Blurton-Jones M, Tuszynski MH. 2001. Reactive astrocytes express estrogen receptors in the injured primate brain. J Comp Neurol 433:115-123.
30. 1-42 activates CaV2.2 (N-type)-voltage operated calcium channels and acutely increases glutamate and noradrenaline release. J Alzheimer's Dis 6:243-255.
31. Bora SH, Liu Z, Kecojevic A, Merchenthaler I, Koliatsos VE. 2005. Direct, complex effect of estrogens on basal forebrain cholinergic neurons. Exp Neurol 194:506-522.
32. [MAPK]/NFκB cascade Aging Cell 4:113-118.
33. 0-ATPase (ATPase) activities in platelets and brain from patients with Alzheimer's disease. Neurobiol Aging 23:371-376.
34. Boulware MI, Weick JP, Becklund BR, Kuo SP, Groth RD, Mermelstein PG. 2005. Estradiol activates group I and II metabotropic glutamate receptor signaling, leading to opposing influences on cAMP response element-binding protein. J Neurosci 25:5066-5078.
35. Boyd-Kimball D, Castegna A, Sultana R, Poon HF, Petroze R, Lynn BC, Klein JB, Butterfield DA. 2005a. Proteomic identification of proteins oxidized by Aβ(1-42) in synaptosomes: Implications for Alzheimer's disease. Brain Res 1044:206-215.
36. Boyd-Kimball D, Sultana R, Poon HF, Lynn BC, Casamenti F, Pepeu G, Klein JB, Butterfield DA. 2005b. Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid β-peptide (1-42) into rat brain: implications for Alzheimer's disease. Neuroscience 132:313-324.
37. Breuer H, Schott E. 1966. Studies of the metabolism of 17 alpha-estradiol in man. J Clin Endocrinol Metab 26:533-536.
38. Brewer GJ, Reichensperger JD, Brinton RD. 2006. Prevention of age-related dysregulation of calcium dynamics by estrogen in neurons. Neurobiol Aging 27:306-317.
39. Brinton RD. 1993. 17β-Estradiol induction of filopodial growth in cultured hippocampal neurons within minutes of exposure. Mol Cell Neurosci 4:36-16.
40. Brinton RD, Tran J, Proffitt P, Montoya M. 1997. 17β-Estradiol enhances the outgrowth and survival of neocortical neurons in culture. Neurochem Res 22:1339-1351.
41. Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE. 2005. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol 57:695-703.
42. Bucciantini M, Calloni G, Chiti F, Formigli L, Nosi D, Dobson CM, Stefani M. 2004. Prefibrillar amyloid protein aggregates share common features of cytotoxicity. J Biol Chem 279:31374-31382.
43. Buckner RL. 2004. Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate. Neuron 44:195-208.
44. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. 2005. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 25:7709-7717.
45. Burkhardt MS, Foster JK, Laws SM, Baker LD, Craft S, Gandy SE, Stuckey BGA, Clarnette R, Nolan D, Hewson-Bower B, Martins RN. 2004. Oestrogen replacement therapy may improve memory functioning in the absence of APOE å4. J Alzheimer's Dis 6:221-228.
46. Busciglio J, Pelsman A, Wong C, Pigino G, Yuan M, Mori H, Yankner BA. 2002. Altered metabolism of the amyloid β precursor protein is associated with mitochondrial dysfunction in Down's Syndrome. Neuron 33:677-688.
47. Bussiere T, Giannakopoulos P, Bouras C, Perl DP, Morrison JH, Hof PR. 2003. Progressive degeneration of nonphosphorylated neurofilament protein-enriched pyramidal neurons predicts cognitive impairment in Alzheimer's disease: stereologic analysis of prefrontal cortex area 9. J Comp Neurol 463:281-302.
48. Bush AI. 2003. The metallobiology of Alzheimer's disease. Trends Neurosci 26:207-214.
49. Bush AI. 2004. Serum copper. A biomarker for Alzheimer disease? Arch Neurol 61:631-632.
50. Cai D, Leem JY, Greenfield JP, Wang P, Kim BS, Wang R, Lopes KO, Kim S-H, Zheng H, Greengard P, Sisodia SS, Thinakaran G, Xu H. 2005. Presenilin-1 regulates intracellular trafficking and cell surface delivery of β-amyloid precursor protein. J Biol Chem 278:3446-3454.
51. Canevari L, Abramov AY, Duchen MR. 2004. Toxicity of amyloid β peptide: tales of calcium, mitochondria, and oxidative stress. Neurochem Res 29:637-650.
52. Cardona-Gomez P, Perez M, Avila J, Garcia-Segura LM, Wandosell F. 2005. Estradiol inhibits GSK3 and regulates interaction of estrogen receptors, GSK3, and beta-catenin in the hippocampus. Mol Cell Neurosci 25:363-373.
53. Cardoso SM, Proenca MT, Santos S, Santana I, Oliveira CR. 2004. Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiol Aging 25:105-110.
54. Casley CS, Canevari L, Land JM, Clark JB, Sharpe MA. 2002. β-Amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J Neurochem 80:91-100.
55. Chen JQ, Delannoy M, Cooke C, Yager JD. 2004. Mitochondrial localization of Erα and Erβ in human MCF7 cells. Am J Physiol Endocrinol Metab 286:E1011-E1022.
56. Choi JM, Romeo RD, Brake WG, Bethea CL, Rosenwaks Z, McEwen BS. 2003. Estradiol increases pre- and post-synaptic proteins in the CA1 region of the hippocampus in female rhesus macaques (Macaca mulatta). Endocrinology 144: 4734-4738.
57. Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. 2005. Synaptic activity regulates interstitial fluid amyloid-β levels in vivo. Neuron 48:913-922.
58. Citron M. 2004. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 5:677-685.
59. Clarkson TB, Appt SE. 2005. Controversies about HRT: lessons from monkey models. Maturitas 51:64-74.
60. Coma M, Guix FX, Uribesalgo I, Espuna G, Sole M, Andreu D, Munoz FJ. 2005. Lack of oestrogen protection in amyloid-mediated endothelial damage due to protein nitrotyrosination. Brain 128:1613-1621.
61. Cooke BM, Woolley CS. 2005. Gonadal hormone modulation of dendrites in the mammalian CNS. J Neurobiol 64:34-46.
62. Cordey M, Pike CJ. 2005. Neuroprotective properties of selective estrogen receptor agonists in cultured neurons. Brain Res 1045:217-223.
63. Cordey M, Gundimeda U, Gopalakrishna R, Pike CJ. 2005. The synthetic estrogen 4-estren-3α, 17β-diol (estren) induces estrogen-like neuroprotection. Neurobiol Dis 19:331-339.
64. Coskun PE, Beal MF, Wallace DC. 2004. Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci USA 101:10726-10731.
65. Cottrell BA, Galvan V, Banwait S, Gorostiza O, Lombardo CR, Williams T, Schilling B, Peel A, Gibson B, Koo EH, Link CD, Bredesen DE. 2005. A pilot proteomic study of amyloid precursor interactions in Alzheimer's disease. Ann Neurol 58: 277-289.
66. Cottrell DA, Blakely EL, Johnson MA, Ince PG, Turnbull DM. 2001. Mitochondrial enzyme-deficient hippocampal neurons and choroidal cells in AD. Neurology 57:260-264.
67. Craig MC, Maid PM, Murphy DGM. 2005. The Women's Health Initiative Memory Study: findings and implications for treatment. Lancet Neurol 4:190-194.
68. Cummings JL. 2004. Alzheimer's disease. N Eng J Med 351: 56-67.
69. Dai J, Buijs RM, Kamphorst W, Swaab DF. 2002. Impaired axonal transport of cortical neurons in Alzheimer's disease is associated with neuropathological changes. Brain Res 948:138-144.
70. Daniel JM, Dohanich GP. 2001. Acetylcholine mediates the estrogen-induced increase in NMDA receptor binding in CA1 of the hippocampus and associated improvement in working memory. J Neurosci 21:6949-6956.
71. Daniel JM, Hulst JL, Berbling JL. 2006. Estradiol replacement enhances working memory in middle-aged rats when initiated immediately after ovariectomy but not after a long-term period of ovarian hormone deprivation. Endocrinology 147:607-614.
72. Davis DM, Jacobson TK, Aliakbari S, Mizumori SJY. 2005. Differential effects of estrogen on hippocampal- and striatal-dependent learning. Neurobiol Learn Memory 84:132-137.
73. DeKosky ST. 2004. Pathology and pathways of Alzheimer's disease with an update on new developments in treatment. J Am Geriatr Soc 51:8314-8320.
74. Delatour B, Blanchard V, Pradier L, Duyckaerts C. 2004. Alzheimer pathology disorganizes cortico-cortical circuitry: direct evidence from a transgenic animal model. Neurobiol Dis 16:41-47.
75. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG. 2005. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 280:17294-17300.
76. Den Heijer T, Geerlings MI, Hofman A, de Jong FH, Launer LJ, Pols HAP, Breteler MMB. 2003. Higher estrogen levels are not associated with larger hippocampi and better memory performance. Arch Neurol 60:213-220.
77. Dhandapani KM, Wade FM, Mahesh VB, Brann DW. 2005. Astrocyte-derived transforming growth factor-β mediates the neuroprotective effects of 17β-estradiol: involvement of nonclassical genomic signaling pathways. Endocrinology 146:2749-2759.
78. Dickson DW. 2001. Neuropathology of Alzheimers disease and other dementias. Clin Geriatr Med 17:209-228.
79. Dougherty JJ, Wu J, Nichols RA. 2003. β-Amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. J Neurosci 23:6740-6747.
80. Dykens JA, Carroll AK, Wiley S, Covey DF, Cai ZY, Zhao L, Wen R. 2004. Photoreceptor preservation in the S334ter model of retinitis pigmentosa by a novel estradiol analog. Biochem Pharmacol 68: 1971-1984.
81. Dykens JA, Moos WH, Howell N. 2005. Developmental of 17α-estradiol as a neuroprotective therapeutic agent. Rationale and results from a phase I clinical study. Ann NY Acad Sci 1052: 116-135.
82. Eberling JL, Wu C, Tong-Turnbeaugh R, Jagust WJ. 2004. Estrogen- and tamoxifen-associated effects on brain structure and function. NeuroImage 21:364-371.
83. Erickson KI, Colcombe SJ, Raz N, Korol DL, Scalf P, Webb A, Cohen NJ, McAuley E, Kramer AF. 2005. Selective sparing of brain tissue in postmenopausal women receiving hormone replacement therapy. Neurobiol Aging 26:1205-1213.
84. Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, Hsia J, Margolis KL, Hogan PE, Wallace R, Dailey M, Freeman R, Hays J for the Women's Health Initiative Memory Study Investigators. 2004. Conjugated equine estrogens and global cognitive function in postmenopausal women. Women's Health Initiative Memory Study. J Am Med Assoc 291:2959-2968.
85. Esteban JA. 2004. Living with the enemy: a physiological role for the β-amyloid peptide. Trends Neurosci 27:1-3.
86. Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, Eckman CB, Tanzi RE, Selkoe DJ. 2004. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid β-protein. Am J Pathol 164:1425-1434.
87. Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Xu Y, Schwam EM, Shah S, Mastey V for the Donepezil MSAD Study Investigators Group. 2004. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology 63:644-650.
88. Fellgiebel A, Muller MJ, Wille P, Dellani PR, Scheurich A, Schmidt LG, Stoeter P. 2005. Color-coded diffusion-tensor-imaging of posterior cingulated fiber tracts in mild cognitive impairment. Neurobiol Aging 26:1193-1198.
89. Fleisher A, Grundman M, Jack CR, Petersen RC, Taylor C, Kim HT, Schiller DHB, Bagwell V, Sencakova D, Weiner MF, DeCarli C, DeKosky ST, van Dyck CH, Thal LJ, for the Alzheimer's Disease Cooperative Study. 2005. Sex, apolipoprotein E ε4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol 62:953-957.
90. 1-42-induced increase in the level of acetylcholinesterase in primary cortical neurons. J Neurochem 88:1186-1193.
91. Foy MR. 2001. 17beta-estradiol: effect on CA1 hippocampal synaptic plasticity. Neurobiol Learn Memory 76:239-252.
92. Foy MR, Xu J, Xie X, Brinton RD, Thompson RF, Berger TW. 1999. 17beta-estradiol enhances NMDA receptor-mediated EPSPs and long-term potentiation. J Neurophysiol 81:925-929.
93. Frick KM, Fernandez SM, Bennett JC, Prange-Kiel J, MacLusky NJ, Leranth C. 2004. Behavioral training interferes with the ability of gonadal hormones to increase CA1 spine density in overiectomized female rats. Eur J Neurosci 19:3026-3032.
94. Frolich L. 2002. The cholinergic pathology in Alzheimer's disease: discrepancies between clinical experience and pathophysiological findings. J Neural Trans 109:1003-1014.
95. Gabor R, Nagle R, Johnson DA, Gibbs RB. 2003. Estrogen enhances potassium-stimulated acetylcholine release in the rat hippocampus. Brain Res 962:244-247.
96. Gaucher SP, Taylor SW, Fahy E, Zhang B, Warnock DE, Ghosh SS, Gibson BW. 2004. Expanded coverage of the human heart mitochondrial proteome using multidimensional liquid chromatography coupled with tandem mass spectrometry. J Proteome Res 3:495-505.
97. Gazzaley A, Kay S, Benson DL. 2002. Dendritic spine plasticity in hippocampus. Neuroscience 111:853-862.
98. Geerlings MI, Launer LJ, de Jong FH, Ruitenberg A, Stijnen T, van Swieten JC, Hofman A, Witteman JCM, Pols HAP, Breteler MMB. 2003. Endogenous estradiol and risk of dementia in women and men: the Rotterdam study. Ann Neurol 53: 607-615.
99. Ghidoni R, Gasparini L, Alberici A, Benussi L, Barbiero L, Mazzoli F, Nicosia F, Finazzi D, Benerini Gatta L, Albertini A, Zanetti O, Binetti G. 2003. Inhibition of energy metabolism down-regulates the Alzheimer related presenilin 2 gene. J Neural Trans 110:1029-1039.
100. Ghisletti S, Meda C, Maggi A, Vegeto E. 2005. 17β-estradiol inhibits inflammatory gene expression by controlling NF-κB intracellular localization. Mol Cell Biol. 25:2957-2968.
101. Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, Morrison JH, Gold G, Hof PR. 2003. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60:1495-1500.
102. Gibbs RB, Gabor R. 2003. Estrogen and cognition: applying preclinical findings to clinical perspectives. J Neurosci Res 74:637-643.
103. Goodenough S, Schleusner D, Pietrzik C, Skutella T, Behl C. 2005. Glycogen synthase kinase 3β links neuroprotection by 17β-estradiol to key Alzheimer processes. Neuroscience 132:581-589.
104. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghof E, Wenger N for the HERS Research Group. 2002. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen/progestin replacement study follow-up (HERS II). J Am Med Assoc 288:49-57.
105. Green PS, Bales K, Paul S, Bu G. 2005. Estrogen therapy fails to alter amyloid deposition in the PDAPP model of Alzheimer's disease. Endocrinology 146:2774-2781.
106. Gu Y, Sanjo N, Chen F, Hasegawa H, Petit A, Ruan X, Li W, Shier C, Kawarai T, Schmitt-Ulms G, Westaway D, St George-Hyslop P, Fraser PE. 2004. The presenilin proteins are components of multiple membrane-bound complexes that have different biological activities. J Biol Chem 279:31329-31336.
107. Hao J, Janssen WGM, Tang Y, Roberts JA, McKay H, Lasley B, Allen PB, Greengard P, Rapp PR, Kordower JH, Hof PR, Morrison JH. 2003. Estrogen increases the number of spinophilin-immunoreactive spines in the hippocampus of young and aged female rhesus monkeys. J Comp Neurol 465:540-550.
108. Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356.
109. Harman SM, Brinton EA, Clarkson T, Heard CB, Hecht HS, Karas RH, Judelson DR, Naftolin F. 2004. Is the WHI relevant to HRT started in perimenopause? Endocrine 24:195-202.
110. Hashimoto M, Rockenstein E, Crews L, Masliah E. 2003. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinsons diseases. NeuroMol Med 4:21-35.
111. Heikkinen T, Kalesnykas G, Rissanen A, Tapiola T, Iivonen S, Wang J, Chaudhuri J, Tanila H, Miettinen R, Puolivali J. 2004. Estrogen improves spatial learning in APP+PS1 mice but does not affect beta amyloid accumulation and plaque formation. Exp Neurol 187:105-117.
112. Henderson VW. 2000. Oestrogens and dementia. Novartis Found Symp 230:254-265.
113. Henderson VW, Benke KS, Green RC, Cupples LA, Farrer LA for the MIRAGE Study Group. 2005. Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. J Neurol Neurosurg Psychiatry 76:103-105.
114. Hillisch A, Peters O, Kosemund D, Muller G, Walter A, Schneider B, Reddersen G, Elger W, Fritzmeier K-H. 2004. Dissecting physiological roles of estrogen receptor α and β with potent selective ligands from structure-based design. Mol Endocrinol 18:1599-1609.
115. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PLR, Jones PK, Petersen RB, Perry G, Smith MA. 2001. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21:3017-3023.
116. Hobe G, Schon R, Goncharov N, Katsiya G, Koryakin M, Gesson-Cholat I, Oettel M, Zimmerman H. 2002. Some new aspects of 17α-estradiol metabolism in man. Steroids 67:889-893.
117. Hogervorst E, Williams J, Budge M, Riedel W, Jolles J. 2000. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience 101:485-512.
118. Honer WG. 2004. Pathology of presynaptic proteins in Alzheimer's disease: more than a simple loss of terminals. Neurobiol Aging 24:1047-1062.
119. Horowitz PM, Patterson KR, Guillozet-Bongaarts AL, Reynolds MR, Carroll CA, Weintraub ST, Bennett DA, Cryns VL, Berry RW, Binder LI. 2004. Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer's disease. J Neurosci 24:7895-7902.
120. Horsburgh K, Macrae IM, Carswell H. 2002. Estrogen is neuroprotective via an apolipoprotein E-dependent mechanism in a mouse model of global ischemia. J Cereb Blood Flow Metab 22:1189-1195.
121. Hully S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunninghake D for the HERS Research Group. 2002. J Am Med Assoc 288:58-66.
122. Iadecola C. 2004. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 5:347-360.
123. Ikonomovic MD, Mufson EJ, Wuu J, Cochran EJ, Bennett, DeKosky ST. 2003. Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: correlation with Alzheimer's neuropathology. J Alzheimer's Dis 5:39-48.
124. Johannsen P. 2004. Long-term cholinesterase inhibitor treatment of Alzheimer's disease. CNS Drugs 18:757-768.
125. John E. 1996. Reassessing Anglo-Saxon England. Manchester, UK: Manchester University Press. 5p.
126. Kamal A, Almenar-Queralt A, LeBlanc JF, Roberts EA, Goldstein LSB. 2001. Kinesin-mediated axonal transport of a membrane compartment containing β-secretase and presenilin-1 requires APP. Nature 414:643-648.
127. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. 2003. APP processing and synaptic function. Neuron 37:925-927.
128. Kang JH, Weuve J, Grodstein F. 2004. Postmenopausal hormone therapy and risk of cognitive decline in community-dwelling aging women. Neurology 63:101-107.
129. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, Markesbery WR. 2005. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64:1152-1156.
130. Kelly MJ, Qiu J, Ronnekleiv OK. 2003. Estrogen modulation of G-protein-coupled receptor activation of potassium channels in the central nervous system. Ann NY Acad Sci 1007:6-16.
131. Klein WL, Stine WB, Teplow DB. 2004. Small assemblies of unmodified amyloid β-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging 25:569-590.
132. Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ. 2005. Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo. Nat Med 11:556-561.
133. Koo EH. 2002. The β-amyloid precursor protein (APP) and Alzheimer's disease: does the tail wag the dog? Traffic 3:763-770.
134. Korol DL. 2004. Role of estrogen in balancing contributions from multiple memory systems. Neurobiol Learn Mem 82:309-323.
135. Kretz O, Fester L, Wehrenberg U, Zhou L, Brauckmann S, Zhao S, Prange-Kiel J, Naumann T, Jarry H, Frotscher M, Rune GM. 2004. Hippocampal synapses depend on hippocampal estrogen synthesis. J Neurosci 24:5913-5921.
136. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GE, Klein WL. 2004. Synaptic targeting by Alzheimer's-related amyloid β oligomers. J Neurosci 24:10191-10200.
137. Lahiri DK, Sambamurti K, Bennett DA. 2004. Apolipoprotein and its interaction with the environmentally driven risk factors: molecular, genetic and epidemiological studies of Alzheimer's disease. Neurobiol Aging 25:651-660.
138. Lamprecht R, LeDoux J. 2004. Structural plasticity and memory. Nat Rev Neurosci 5:45-54.
139. Lansbury PT. 2004. Back to the future: the "old-fashioned" way to new medications for neurodegeneration. Nat Rev Neurosci 5(Suppl):S51-S57.
140. Lazarov O, Morfini GA, Lee EB, Farah MH, Szodorai A, DeBoer SR, Koliatsos VE, Kins S, Lee V M-Y, Wong PC, Price DL, Brady ST, Sisodia SS. 2005. Axonal transport, amyloid precursor protein, kinesis-1, and the processing apparatus: revisited. J Neurosci 25: 2386-2395.
141. LeBlanc ES, Janowsky J, Chan BKS, Nelson HD. 2001. Hormone replacement therapy and cognition. Systematic review and meta-analysis. J Am Med Assoc 285:1489-1499.
142. Lee H, Casadeus G, Zhu X, Joseph JA, Perry G, Smith MA. 2004. Perspectives on the amyloid-β cascade hypothesis. J Alzheimer's Dis 6:137-145.
143. Lee SJ, McEwen BS. 2001. Neurotrophic and neuroprotective actions of estrogens and their therapeutic implications. Annu Rev Pharmacol Tox 41:569-591.
144. Lee SJ, Campomanes CR, Sikat PT, Greenfield AT, Allen PB, McEwen BS. 2004. Estrogen induces phosphorylation of cyclic AMP response element binding (pCREB) in primary hippocampal cells in a time-dependent manner. Neuroscience 124:549-560.
145. Levens E, Williams RS. 2004. Current opinions and understandings of menopausal women about hormone replacement therapy (HRT): The University of Florida experience. Am J Obstet Gyn 191:841-847.
146. Levin ER. 2005. Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol 19:1951-1959.
147. Levin-Allerhand J, McEwen BS, Lominska CE, Lubahn DB, Korach KS, Smith JD. 2001. Brain region-specific up-regulation of mouse apolipoprotein E by pharmacological estrogen treatments. J Neurochem 79:796-803.
148. Levin-Allerhand JA, Lominska CE, Wang J, Smith JD. 2002. 17α-estradiol and 17β-estradiol treatments are effective in lowering cerebral amyloid-β levels in AβPPSWE transgenic mice. J Alzheimer's Dis 4:449-457.
149. LeVine H. 2004. The Amyloid Hypothesis and the clearance and degradation of Alzheimer's β-peptide. J Alzheimer's Dis 6: 303-314.
150. Li C, Brake WG, Romeo RD, Dunlop JC, Gordon M, Buzescu R, Magarinos AM, Allen PB, Greengard P, Luine V, McEwen BS. 2004a. Estrogen alters hippocampal dendritic spine shape and enhances synaptic protein immunoreactivity and spatial memory in female mice. Proc Natl Acad Sci USA 101:2185-2190.
151. Li F, Calingasan NY, Yu F, Mauck WM, Todize M, Almeida CG, Takahashi RH, Carlson GA, Beal MF, Lin MT, Gouras GK. 2004b. Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice. J Neurochem 89: 1308-1312.
152. Liao L, Cheng D, Wang J, Duong DM, Losik TG, Gearing M, Rees HD, Lah JJ, Levey AI, Peng J. 2004. Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. J Biol Chem 279:37061-37068.
153. Liu L, Wong TP, Pozza MF, Lingenhoehl K, Wang Y, Sheng M, Auberson YP, Wang YT. 2004. Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science 304:1021-1024.
154. Liu Q, Smith MA, Avila J, DeBernardis J, Kansal M, Takeda A, Zhu X, Nunomura A, Honda K, Moreira PI, Oliveira CR, Santos MS, Shimohama S, Aliev G, de la Torre J, Ghanbari HA, Siedlak SL, Harris PLR, Sayre LM, Perry G. 2005. Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations. Free Rad Biol Med 38:746-754.
155. Lopez OL, Becker JT, Saxton J, Sweet RA, Klunk W, DeKosky ST. 2005. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition. J Am Geriatr Soc 53:83-87.
156. Lovell MA, Xiong S, Markesbery WR, Lynnn BC. 2005. Quantitative proteomic analysis of mitochondria from primary neuron cultures treated with amyloid beta peptide. Neurochem Res 30:113-122.
157. Luine VN, Jacome LF, MacLusky NJ. 2003. Rapid enhancement of visual and place memory by estrogens in rats. Endocrinology 144:2836-2844.
158. Lustbader JW, Cirilli M, Lin C, Xi HW, Takuma K, Wang N, Caspersen C, Chen X, Pollak S, Chaney M, Trinchese F, Liu S, Gunn-Moore F, Lue L-F, Walker DG, Kuppusamy P, Zewier ZL, Arancio O, Stern D, Yan SS, Wu H. 2004. ABAD directly links Aβ to mitochondrial toxicity in Alzheimer's disease. Science 304:448-452.
159. MacLusky NJ. 2004. Estrogen and Alzheimer's disease: the apolipoprotein connection. Endocrinology 145:3062-3064.
160. MacLusky NJ, Luine V, Hajszan T, Leranth C. 2005. The 17α and 17β isomers of estradiol both induce rapid spine synapse formation in the CA1 hippocampal subfield of ovariectomized female rats. Endocrinology 146:287-293.
161. Mandavilli A. 2006. Hormone in the hot seat. Nature Med 12:8-9.
162. Massey PV, Johnson BE, Moult PR, Auberson YP, Brown MW, Molnar E, Collingridge GL, Bashir ZI. 2004. Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression. J Neurosci 24; 7821-7828.
163. Mattson MP. 2004. Pathways towards and away from Alzheimer's disease. Nature 430:631-639.
164. Mayeux R. 2003. Epidemiology of neurodegeneration. Annu Rev Neurosci 26:81-104.
165. McDevitt RE, Malamas MS, Manas ES, Unwalla RJ, Xu ZB, Miller CP, Harris HA. 2005. Estrogen receptor ligands: design and synthesis of new 2-arylindene-1-ones. Bioorg Med Chem Lett 15: 3137-3142.
166. McEwen B. 2002. Estrogen actions throughout the brain. Recent Prog Horm Res 57:357-384.
167. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, DeLucia M, Lin W-L, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T. 2005. Aβ42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47:191-199.
168. Medunjanin S, Hermani A, De Servi B, Grisouard J, Rincke G, Mayer D. 2005. Glycogen synthase kinase-3 interacts with and phosphorylates estrogen receptor α and is involved in the regulation of receptor activity. J Biol Chem 280:33006-330014.
169. Meek PD, McKeithan K, Schumock GT. 1998. Economic considerations in Alzheimer's disease. Pharmacotherapy 18:68-73.
170. Mesulam M-M. 1999. Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron 24:521-529.
171. Mesulam M. 2004. The cholinergic lesion of Alzheimer's disease: pivotal factor or side show? Learn Memory 11:43-49.
172. Migliore L, Fontana I, Trippi F, Colognato R, Coppede F, Tognoni G, Nucciarone B, Siciliano G. 2005. Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol Aging 26:567-575.
173. Miller MI, Hosakere M, Barker AR, Priebe CE, Lee N, Ratnanather JT, Wang L, Gado M, Morris JC, Csernansky JG. 2003. Labeled cortical mantle distance maps of the cingulate quantify differences between dementia of the Alzheimer type and healthy aging. Proc Natl Acad Sci USA 100:15172-15177.
174. Million Women Study Collaborators. 2003. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419-427.
175. Milner TA, McEwen BS, Hayashi S, Li CJ, Reagan LP, Alves SE. 2001. Ultrastructural evidence that hippocampal alpha estrogen receptors are located at extranuclear sites. J Comp Neurol 429: 355-371.
176. Milner TA, Ayoola K, Drake CT, Herrick SP, Tabori NE, McEwen BS, Warrier S, Alves SE. 2005. Ultrastructural localization of estrogen receptor β immunoreactivity in the rat hippocampal formation. J Comp Neurol 491:81-95.
177. Milton NGN. 2004. Role of hydrogen peroxide in the aetiology of Alzheimers disease. Implications for treatment. Drugs Aging 21:81-100.
178. Mishizen-Eberz AJ, Rissman RA, Carter TL, Ikonomovic MD, Wolfe BB, Armstrong DM. 2004. Biochemical and molecular studies of NMDA receptor subunits NR1/2A/2B in hippocampal subregions throughout progression of Alzheimer's disease pathology. Neurobiol Aging 15:80-92.
179. Modena MG, Sisondi P, Mueck AO, Kuttenn F, de Lignieres B, Verhaeghe J, Foidart JM, Caufriez A, Genazzani AR. The TREAT Collaborative Study Group. 2005. New evidence regarding hormone replacement therapies is urgently required. Transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas 52:1-10.
180. Monk D, Brodaty H. 2000. Use of estrogens for the prevention and treatment of Alzheimer's disease. Dement Geriatr Cogn Disord 11:1-10.
181. Moolman DL, Vitolo OV, Vonsattel J-Pg, Shelanski ML. 2004. Dendrite and dendritic spine alterations in Alzheimer models. J Neurocytol 33:377-387.
182. Morfini G, Szebenyi G, Brown H, Pant HC, Pigino G, DeBoer S, Beffert U, Brady ST 2004. A novel CDK5-dependent pathway for regulating GSK3 activity and kinesin-driven motility in neurons. EMBO J 23:2235-2245.
183. Morrison JH, Hof PR. 1997. Life and death of neurons in the aging brain. Science 278:412-419.
184. Morse JK, Scheff SW, DeKosky ST. 1986. Gonadal steroids influence axon sprouting in the hippocampal dentate gyrus: a sexually dimorphic response. Exp Neurol 94:649-658.
185. Murray IVJ, Sindoni ME, Axelsen PH. 2005. Promotion of oxidative lipid membrane damage by amyloid β proteins. Biochemistry 44: 12606-12613.
186. Naftolin F, Taylor HS, Karas R. 2004. Early initiation of hormone therapy and clinical cardioprotection: the Women's Health Initiative (WHI) could not have detected cardioprotective effects starting hormone therapy during the menopausal transition. Fertil Steril 81:1498-1501.
187. 1-42 in neurons is facilitated by the α7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience 110:199-211.
188. Nagele RG, Wegiel J, Venkataraman V, Imaki H, Wang K-C, Wegiel J. 2004. Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. Neurobiol Aging 25:663-674.
189. Nathan BP, Barsukova AG, Shen F, McAsey M, Strahle RG. 2004. Estrogen facilitates neurite extension via apolipoprotein E in cultured adult mouse cortical neurons. Endocrinology 145:3065-3073.
190. Nestor PJ, Scheltens P, Hodges JR. 2004. Advances in the early detection of Alzheimer's disease. Nat Rev Neurosci 5(Suppl):S34-S41.
191. Nilsen J, Brinton RD. 2002. Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterpne and antagonism by medroxyprogesterone acetate. Endocrinology 143:205-212.
192. Nilsen J, Brinton RD. 2003. Mechanism of estrogen-mediated neuroprotection: regulation of mitochondrial calcium and Bcl-2 expression. Proc Natl Acad Sci USA 100:2842-2847.
193. Nilsen J, Brinton RD. 2004. Mitochondria as therapeutic targets of estrogen action in the central nervous system. Curr Drug Targets CNS Neurol Dis 3:297-313.
194. Nunomura A, Chiba S, Lippa CF, Cras P, Kalaria RN, Takeda A, Honda K, Smith MA, Perry G. 2004. Neuronal RNA oxidation is a prominent feature of familial Alzheimer's disease. Neurobiol Dis 17:108-113.
195. Parker WD Jr, Filley CM, Parks JK. 1990. Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 40:1302-1303.
196. Parker WD Jr, Parks JK, Filley CM, Kleinschmidt-Demasters BK. 1994. Electron transport chain defects in Alzheimer's disease brain. Neurology 44:1090-1096.
197. Pazol K, Wilson ME, Wallen K. 2004. Medroxyprogesterone acetate antagonizes the effects of estrogen treatment on social and sexual behavior in female macaques. J Clin Endocrin Metab 89:2998-3006.
198. Pedersen NL, Gatz M, Berg S, Johansson B. 2004. How heritable is Alzheimer's disease late in life? Findings from Swedish twins. Ann Neurol 55:180-185.
199. Perlman WR, Matsumoto M, Beltaifa S, Hyde TM, Saunders RC, Webster MJ, Rubinow DR, Kleinman JE, Weickert CS. 2005. Expression of estrogen receptor alpha exon-deleted mRNA variants in the human and non-human primate frontal cortex. Neuroscience 134:81-95.
200. Piccini A, Russo C, Gliozzi A, Relini A, Vitali A, Borghi R, Giliberto L, Armirotti A, D'Arrigo C, Bachi A, Cattaneo A, Canale C, Torrassa S, Saido TC, Markesbery W, Gambetti P, Tabaton M. 2005. β-amyloid is different in normal aging and in Alzheimer disease. J Biol Chem 280:34186-34192.
201. 2+-calmodulin-dendent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. J Neurosci 24:5283-5291.
202. Pigino G, Morfini G, Pelsman A, Mattson MP, Brady ST, Busciglio J. 2003. Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport. J Neurosci 23:4499-4508.
203. Plant LD, Boyle JP, Smith IF, Peers C, Pearson HA. 2003. The production of amyloid β peptide is a critical requirement for the viability of central neurons. J Neurosci 23:5531-5535.
204. Prange-Kiel J, Rune GM, Leranth C. 2004. Median raphe mediates estrogenic effects to the hippocampus in female rats. Eur J Neurosci 19:309-317.
205. Preziosi P. 2004. Science, pharmacoeconomics and ethics in drug R&D: a sustainable future scenario? Nat Rev Drug Disc 3:521-526.
206. Puzzo D, Vitolo O, Trinchese F, Jacob JP, Palmeri A, Arancio O, 2005. Amyloid-β peptide inhibits activation of the nitric oxide/cGMP/cAMP- responsive element-binding protein pathway during hippocampal synaptic plasticity. J Neurosci 25:6887-6897.
207. Qiu Z, Hyman BT, Rebeck GW. 2004. Apolipoprotein E receptors mediate neurite outgrowth through activation of p44/p42 mitogen-activated protein kinase in primary neurons. J Biol Chem 279:34948-34956.
208. 2-isoprostanes in Alzheimers disease. J Alzheimer's Dis 6:93-97.
209. Rapp PR, Morrison JH, Roberts JA. 2003a. Cyclic estrogen replacement improves cognitive function in aged ovariectomized rhesus monkeys. J Neurosci 23:5708-5714.
210. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass MLS, Lane DS, Hays J, Johnson KC, Coker LH, dailey M, Bowen D for the WHIMS Investigators. 2003b. Effect of estrogen plus progestin on global cognitive function in postmenopausal women. The Women's Health Initiative Memory Study: A Randomized Controlled Trial. J Amer Med Assoc 289:2662-2672.
211. Rasgon NL, Silverman D, Siddarth P, Miller K, Ercoli LM, Elman S, Lavretsky H, Huang S-C, Phelps ME, Small GW. 2005. Estrogen use and brain metabolic change in postmenopausal women. Neurobiol Aging 26:229-235.
212. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. 2005. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307:1625-1630.
213. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li Q-X, Tammer A, Carrington D, Mavros C, Volitalds I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL. 2003. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease. Arch Neurol 60:1685-1691.
214. Rockenstein E, Mante M, Alford M, Adame A, Crews L, Hashimoto M, Esposito L, Mucke L, Masliah E. 2005. High β-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-β levels. Implications for the treatment of Alzheimer disease. J Biol Chem 280:32957-32967.
215. Rogaeva EA, Fafel KC, Song YQ, Medeiros H, Sato C, Liang Y, Richard E, Rogaev EI, Frommelt P, Sadovnick AD, Meschino W, Rockwood K, Boss MA, Mayeux R, St George-Hyslop P. 2001. Screening of PS1 mutations in a referral-based series of AD cases. 21 novel mutations. Neurology 57:621-625.
216. Rozovsky I, Wei M, Stone DJ, Zanjani H, Anderson CP, Morgan TE, Finch CE. 2002. Estradiol (E2) enhances neurite outgrowth by repressing glial fibrillary acidic protein expression and reorganizing laminin. Endocrinology 143:636-646.
217. Rudick CN, Woolley CS. 2003. Selective estrogen receptor modulators regulate phasic activation of hippocampal CA1 pyramidal cells by estrogen, Endocrinology 144:179-187.
218. Rudick CN, Gibbs RB, Woolley CS. 2003. A role for the basal forebrain cholinergic system in estrogen-induced disinhibition of hippocampal pyramidal cells. J Neurosci 23:4479-4490.
219. Saldanha CJ, Schlinger BA, Micevych PE, Horvath TL. 2004. Presynaptic N-methyl-D-asparate receptor expression is increased by estrogen in an aromatase-rich area of the songbird hippocampus. J Comp Neurol 469:522-534.
220. Salter MW, Kalia LV. 2004. Src kinases: a hub for NMDA receptor regulation. Nat Rev Neurosci 5:317-328.
221. SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH. 2005. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309: 476-481.
222. Saura CA, Choi S-Y, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, Chattarji S, Kelleher RJ, Kandel ER, Duff K, Kirkwood A, Shen J. 2004. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 42:23-36.
223. Saura CA, Chen G, Malkani S, Choi S-Y, Takahashi RH, Zhang D, Gouras GK, Kirkwood A, Morris RGM, Shen J. 2005. Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. J Neurosci 25:6755-6764.
224. Scarabin P-Y, Oger E, Plu-Bureau G, on behalf of the Estrogen and ThromboEmbolism Risk (ESTHER) Study Group. 2003. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 362:428-432.
225. Scharfman HE, MacLusky NJ. 2005. Similarities between actions of estrogen and BDNF in the hippocampus: coincidence or clue? Trends Neurosci 28:79-85.
226. Schenk D, Hagen M, Seubert P. 2004. Current progress in β-amyloid immunotherapy. Curr Opinion Immunol 16:599-606.
227. Schiff R, Bulpitt CJ, Wesnes KA, Rajkumar C. 2005. Short-term transdermal estradiol therapy, cognition and depressive symptoms in healthy older women. A randomized placebo controlled pilot cross-over study. Psychoneuroendocrinology 30:309-315.
228. Schmitz C, Rutten BPF, Pielen A, Schäfer S, Wirths O, Tremp G, Czech C, Blanchard V, Multhaup G, Rezaie P, Korr H, Steinbusch HWM, Pradier L, Bayer TA. 2004. Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. Am J Pathol 164:1495-1502.
229. Schneider LS. 2004. AD2000: Donepezil in Alzheimer's disease (commentary). Lancet 363:2100-2101.
230. Segal M, Murphy D. 2001. Estradiol induces formation of dendritic spines in hippocampal neurons: functional correlates. Hormones Behav 40:156-159.
231. Selkoe DJ. 2002. Alzheimer's disease is a synaptic failure. Science 298:789-791.
232. Serretti A, Artioli P, Quartesan R, De Ronchi D. 2005. Genes involved in Alzheimer's disease, a survey of possible candidates. J Alzheimer's Dis 7:331-353.
233. Sharma PK, Thakur MK. 2005. Expression of estrogen (ER) α and β in mouse cerebral cortex: effect of age, sex and gonadal steroids. Neurobiol Aging (in press).
234. Shea TB, Ortiz D. 2003. 17 β-Estradiol alleviates synergistic oxidative stress resulting from folate deprivation and amyloid-β treatment. J Alzheimer's Dis 5:323-327.
235. Sherwin BB. 2005. Estrogen and memory in women: how can we reconcile the findings? Hormones Behav 47:371-375.
236. Shumaker SA, Reboussin BA, Espeland MA, Rapp SR, McBee WL, Dailey M, Bowen D, Terrell T, Jones BN for the WHIMS Investigators. 1998. The Women's Health Initiative Memory Study (WHIMS): A trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Control Clin Trials 19:604-621.
237. Shumaker SA, Legault C, Rapp SR, Thai L, Wallace RB, Ockene JK, Hendrix SL, Jones BN, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J. 2003. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial. J Am Med Assoc 289:2651-2662.
238. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH for the Women's health Initiative Memory Study Investigators. 2004. Conjugated equine estrogens and incidence of probably dementia and mild cognitive impairment in postmenopausal women. Women's Health Initiative Memory Study. J Am Med Assoc 291:2947-2958.
239. Sievernich A, Wildt L, Lichtenberg-Frate H. 2004. In vitro bioactivity of 17α-estradiol. J Steroid Biochem Mol Biol 92:455-463.
240. Simonian NA, Hyman BT. 1993. Functional alterations in Alzheimer's disease: diminution of cytochrome oxidase in the hippocampal formation. J Neuropath Exp Neurol 52:580-585.
241. Simpkins JW, Wang J, Wang X, Perez E, Prokai L, Dykens JA. 2005. Mitochondria play a central role in estrogen-induced neuroprotection. Curr Drug Targets CNS Neurol Dis 4:69-83.
242. Skouby SO, Al-Azzawi F, Barlow D, Ertungealp JC-AE, Compel A, Graziottin A, Hudita D, Pines A, Rozenberg S, Samsioe G, Stevenson JC. 2005. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas 51:8-14.
243. Small DH. 2004. Do acetylcholinesterase inhibitors boost synaptic scaling in Alzheimer's disease? Trends Neurosci 27:245-249.
244. Small DH, Mok SS, Bornstein JC. 2001. Alzheimer's disease and Aβ toxicity: from top to bottom. Nat Rev Neurosci 2:595-598.
245. Smith CC, McMahon LL. 2005. Estrogen-induced increase in the magnitude of long-term potentiation occurs only when the ratio of NMDA transmission to AMPA transmission is increased. J Neurosci 25:7780-7791.
246. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P. 2005. Regulation of NMDA receptor trafficking by amyloid-β. Nat Neurosci 8:1051-1058.
247. Sortino MA, Chisari M, Merlo S, Vancheri C, Caruso M, Nicoletti F, Canonico PL, Copani A. 2004. Glia mediates the neuroprotective action of estradiol on β-amyloid-induced neuronal death. Endocrinology 145:5080-5086.
248. Speroff L, Kenemans P, Burger HG. 2005. Practical guides for postmenopausal hormone therapy. Maturitas 51:4-7.
249. Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT. 2005. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci 25:7278-7287.
250. Stamer K, Vogel R, Thies E, Mandelow E, Mandelow E-M. 2002. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol 156:1051-1063.
251. Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, Raman R, Davies P, Masliah E, Williams DS, Goldstein LSB. 2005. Axonopathy and transport deficits early in the pathogenesis of Alzheimers disease. Science 307:1282-1288.
252. Studd J. 2003. Up to general practice to pick up the pieces, what pieces?: a response to WHI and WHIMS. Maturitas 46:95-96.
253. Studd J. 2004. Second thoughts on the Women's Health Initiative study: the effect of age on the safety of HRT. Climacteric 7: 412-414.
254. Suo Z, Wu M, Citron BA, Wong GT, Festoff BW. 2004. Abnormality of G-protein-coupled receptor kinases at prodromal and early stages of Alzheimers disease: an association with early β-amyloid accumulation. J Neurosci 24:3444-3452.
255. Sweatt JD. 2004. Mitogen-activated protein kinases in synaptic plasticity and memory. Curr Opin Neurobiol 14:311-317.
256. Tang YP, Haslam SZ, Conrad SE, Sisk CL. 2004. Estrogen increases brain expression of the mRNA encoding transthyretin, an amyloid β scavenger protein. J Alzheimers Dis 6:413-420.
257. Thal L, Thomas RG, Mulnard R, Sano M, Grundman M, Schneider L. 2003. Estrogen levels do not correlate with improvements in cognition. Arch Neurol 60:209-212.
258. The Women's Health Initiative Steering Committee. 2004. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomized Controlled Trial. J Am Med Assoc 291:1701-1712.
259. Tinkler GP, Tobin JR, Voytko ML. 2004. Effects of two years of estrogen loss or replacement on nucleus basalis cholinergic neurons and cholinergic fibers to the dorsolateral prefrontal and inferior parietal cortex of monkeys. J Comp Neurol 469:507-521.
260. Toran-Allerand CD. 2004a. Minireview: a plethora of estrogen receptors in the brain: where will it end? Endocrinology 145:1069-1074.
261. Toran-Allerand CD. 2004b. Estrogen and the brain: beyond ER-α and ER-β. Exp Gerontol 39:1579-1586.
262. Toran-Allerand CD, Tinnikov AA, Singh RJ, Nethrapalli IS. 2005. 17α-estradiol: a brain-active estrogen? Endocrinology 146:3843-3850.
263. Towart LA, Alves SE, Znamensky V, Hayashi S, McEwen BS, Milner TA. 2003. Subcellular relationships between cholinergic terminals and estrogen receptor-α in the dorsal hippocampus. J Comp Neurol 463:390-101.
264. Trimmer PA, Keeney PM, Borland MK, Simon FA, Almeida J, Swerdlow R, Parks JK, Parker WD Jr, Bennett JP. 2004. Mitochondrial abnormalities in cybrid cell models of sporadic Alzheimers disease worsen with passage in culture. Neurobiol Dis 15:29-39.
265. Turgeon JL, McDonnell DP, Martin KA, Wise PM. 2004. Hormone therapy: physiological complexity belies therapeutic simplicity. Science 304:1269-1273.
266. Tuszynski MH, Thai L, Pay M, Salmon DP, Sang-U H, Bakay R, Patel P, Blesch A, Vahlsing HL, Ho G, Tong G, Potkin SG, Fallon J, Hansen L, Mufson EJ, Kordower JH, Gall C, Conner J. 2005. A phase I clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11:551-555.
267. Unger C, Hedberg MM, Mustafiz T, Svedberg MM, Nordberg A. 2005. Early changes in Aβ levels in the brain of APPswe transgenic mice: implication on synaptic density, a7 neuronal nicotinic acetylcholine- and N-methyl-D-aspartate receptor levels. Mol Cell Neurosci 30:218-227.
268. U. S. Preventive Services Task Force. 2005. Hormone therapy for the prevention of chronic conditions in postmenopausal women: Recommendations from the U. S. Preventive Services Task Force. Ann Intern Med 142:855-860.
269. Valla J, Berndt JD, Gonzalez-Lima F. 2001. Energy hypometabolism in posterior cingulate cortex of Alzheimer'a patients: superficial laminar cytochrome oxidase associated with disease duration. J Neurosci 21:4923-4930.
270. Voisin T, Reynish E, Portet F, Feldman H, Vellas B. 2004. What are the treatment options for patients with severe Alzheimer s disease. CNS Drugs 18:575-583.
271. Vongpatanasin W, Tuncel M, Wang Z, Arbique D, Mehrad B, Jialal I. 2003. Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Amer Coll Cardiol 41:1358-1363.
272. Vouimba R-M, Foy MR, Foy JG, Thompson RF. 2000. 17β-Estradiol suppresses expression of long-term depression in aged rats. Brain Res Bull 53:783-787.
273. Wals h DM, Selkoe DJ. 2004. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44:181-193.
274. Wang H, Luo W, Zhang Y, Li Y-M, Thinakaran G, Greengard P, Xu H. 2004. Presenilins and γ-secretase inhibitors affect intracellular trafficking and cell surface localization of the γ-secretase complex components. J Biol Chem 279:40560-40566.
275. 7 Nicotinic acetylcholine receptors mediate β-amyloid peptide-induced tau protein phosphorylation. J Biol Chem 278:31547-31553.
276. Wang J, Green PS, Simpkins JW. 2001. Estradiol protects against ATP depletion, mitochondrial membrane potential decline and the generation of reactive oxygen species induced by 3-nitroproprionic acid in SK-N-SH human neuroblastoma cells. J Neurochem 77:804-811.
277. Wang J, Xiong S, Xie C, Markesbery WR, Lovell MA. 2005. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J Neurochem 93:953-962.
278. Wang Q, Rowan MJ, Anwyl R. 2004. β-Amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthesis and superoxide. J Neurosci 24:6049-6056.
279. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen T, Curb JD, Black H, Rossouw JE, Aragaki A, Safford M, Stein E, Laowattana S, Mysiw WJ, for the WHI Investigators. 2003. Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial. J Am Med Assoc 289:2673-2684.
280. West MJ, Kawas CH, Stewart WF, Rudow GL, Troncoso JC. 2004. Hippocampal neurons in pre-clinical Alzheimer's disease. Neurobiol Aging 25:1205-1212.
281. Williams KI, Layne DS. 1967. Metabolism of 17-alpha-estradiol-6, 7-3H by nonpregnant women. J Clin Endocrinol Metab 27: 159-164.
282. Wimo A. 2004. Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease. A review with methodological considerations. Drugs Aging 21:279-295.
283. Winblad B, Jelic V. 2004. Long-term treatment of Alzheimer disease. Efficacy and safety of acetylcholinesterase inhibitors. Alzheimer Dis Assoc Disord 18:S2-S8.
284. Wise PM, Dubal DB, Wilson ME, Rau SW, Böttner M. 2001. Minireview: Neuroprotective effects of estrogen: new insights into mechanisms of action. Endocrinology 142:969-973.
285. Wong-Riley M, Antuono P, Ho K-C, Egan R, Hevner R, Liebl W, Huang Z, Rachel R, Jones J. 1997. Cytochrome oxidase in Alzheimer's disease: biochemical, histochemical, and immunohistochemical analyses of the visual and other systems. Vision Res 37:3593-3608.
286. Woolley CS. 1998. Estrogen-mediated structural and functional synaptic plasticity in the female rat hippocampus. Hormones Behav 34:140-148.
287. Woolley CS, Gould E, Frankfurt M, McEwen BS. 1990. Naturally-occurring fluctuation in dendritic spine density on adult hippocampal pyramidal neurons. J Neurosci 10:4035-4039.
288. Writing Group for the Women's Health Initiative Investigators. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. J Am Med Assoc 288:321-333.
289. Wu C-C, Chawla F, Games D, Rydel RE, Freedman S, Schenk D, Young WG, Morrison JH, Bloom FE. 2004. Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice: digital morphometric analyses. Proc Natl Acad Sci USA 101: 7141-7146.
290. Wu J, Kuo Y-P, George AA, Xu L, Hu J, Lukas RJ. 2004. β-Amyloid directly inhibits human α4β2-nicotinic acetylcholine receptors heterologously expressed in human SH-EP1 cells. J Biol Chem 279:37842-37851.
291. Wu Z, Guo H, Chow N, Sallstrom J, Bell RD, Deane R, Brooks AI, Kanagala S, Rubio A, Sagare A, Liu D, Li F, Armstrong D, Gasiewicz T, Zidovetzki R, Song X, Hofman F, Zlokovic BV. 2005a. Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat Med 11:959-965.
292. 2+ influx via L-type calcium channels activates the src/ERK/cyclic-AMP response element binding protein signal pathway and Bcl-2 expression in rat hippocampal neurons: a potential initiation mechanism for estrogen-induced neuroprotection. Neuroscience 135:59-72.
293. Xia S, Cai ZY, Thio LL, Kim-Han JS, Dugan LL, Covey DF, Rothman SM. 2002. The estrogen receptor is not essential for all estrogen neuroprotection: new evidence from a new analog. Neurobiol Dis 9:282-293.
294. Yaffe K, Sawaya G, Lieberburg I, Grady D. 1998. Estrogen therapy in postmenopausal women. Effects on cognitive function and dementia. J Am Med Assoc 279:688-695.
295. Yaffe K, Haan M, Byers A, Tangen C, Kuller L. 2000. Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. Neurology 54:1949-1954.
296. Yaffe K, Krueger K, Cummings SR, Blackwell T, Henderson VW, Sarkar S, Ensrud K, Grady D. 2005. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry 162:683-690.
297. Yang S-H, Liu R, Perez EJ, Wen Y, Stevens SM, Valencia T, Brun-Zinkernagel A-M, Prokai L, Will Y, Dykens J, Koulen P, Simpkins JW. 2004. Mitochondrial localization of estrogen receptor β. Proc Natl Acad Sci USA 101:4130-4135.
298. Ye C, Walsh DM, Selkoe DJ, Hartley DM. 2004. Amyloid β-protein induced electrophysiological changes are dependent on aggregation state: N-methyl-D-aspartate (NMDA) versus non-NMDA receptor/channel activation. Neurosci Lett 366:320-325.
299. Yi KD, Chung J, Pang P, Simpkins JW. 2005. Role of protein phosphatases in estrogen-mediated neuroprotection. J Neurosci 25:7191-7198.
300. Yokomaku D, Numakawa T, Numakawa Y, Suzuki S, Matsumoto T, Adachi N, Nishio C, Taguchi T, Hatanaka H. 2003. Estrogen enhances depolarization-induced glutamate release through activation of phosphatidylinositol 3-kinase and mitogen-activated protein kinase in cultured hippocampal neurons. Mol Endocrinol 17:831-844.
301. Yu X, Rajala RVS, McGinnis JF, Li F, Anderson RE, Yan X, Li S, Elias RV, Knapp RR, Zhou X, Cao W. 2004. Involvement of insulin/phosphoinositide 3-kinase/Akt singal pathway in 17β-estradiol-mediated neuroprotection. J Biol Chem 279:13086-13094.
302. Yue X, Lu M, Lancaster T, Cao P, Honda S-I, Staufenbiel M, Harada N, Zhong Z, Shen Y, Li R. 2005. Brain estrogen deficiency accelerates Aβ plaque formation in an Alzheimer's disease animal model. Proc Natl Acad Sci USA 102:19198-19203.
303. Yuen EY, Jiang Q, Feng J, Yan Z. 2005. Microtubule regulation of N-methyl-D-asparate receptor channels in neurons. J Biol Chem 280:29420-29427.
304. Zamani MR, Desmond NL, Levy WB. 2000. Estradiol modulates long-term synaptic depression in female rat hippocampus. J Neurophysiol 84:1800-1808.
305. Zamani MR, Levy WB, Desmond NL. 2004. Estradiol increases delayed, N-methyl-D-aspartate receptor-mediated excitation in the hippocampal CA1 region. Neuroscience 129:243-254.
306. Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, Breitner JCS for the Cache County Memory Study Investigators. 2002. Hormone replacement therapy and incidence of Alzheimer disease in older women. The Cache County Study. J Am Med Assoc 288:2123-2139.
307. Zee RF, Trivedi MA. 2002. The effects of estrogen replacement therapy on neuropsychological functioning in postmenopausal women with and without dementia: a critical and theoretical review. Neuropsychol Rev 12:65-109.
308. Zhao L, Wu T, Brinton RD. 2004. Estrogen receptor subtypes alpha and beta contribute to neuroprotection and increased Bcl-2 expression in primary hippocampal neurons. Brain Res 1010:22-34.
309. 2+ rise and subsequent cyclic AMP response element-binding protein activation in hippocampal neurons: a potential initiation mechanism for estrogen neuroprotection. Neuroscience 132:299-311.
310. Zhu X, Raina AK, Perry G, Smith MA. 2004a. Alzheimer's disease: the two-hit hypothesis. Lancet Neurol 3:219-226.
311. Zhu X, Wang Y, Ogawa O, Lee H, Raina AK, Siedlak SL, Harris PLR, Fujioka H, Shimohama, Tabaton M, Atwood CS, Petersen RB, Perry G, Smith MA. 2004b. Neuroprotective Bcl-w in Alzheimer disease. J Neurochem 89:1233-1240.
312. Zlokovic BV. 2005. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 28:202-208.
313. Znamensky V, Akama KT, McEwen BS, Milner TA. 2003. Estrogen levels regulate the subcellular distribution of phosphorylated Akt in hippocampal dendrites. J Neurosci 23:2340-2347.